Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

27 augustus 2018 bijgewerkt door: Eisai Co., Ltd.

Phase I/II Study of E7080 in Patients With Advanced Hepatocellular Carcinoma (HCC)

The purpose of this study is to determine maximum tolerated dose (MTD), efficacy, safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 when is administered continually once daily in participants with advanced hepatocellular carcinoma.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Werkelijk)

66

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Japan
    • Chiba
      • Kashiwa-shi, Chiba, Japan
    • Fukuoka
      • Kurume-shi, Fukuoka, Japan
    • Hokkaido
      • Sapporo-shi, Hokkaido, Japan
    • Kanagawa
      • Kawasaki-shi, Kanagawa, Japan
    • Osaka
      • Osaka-shi, Osaka, Japan
      • Osakasayama-shi, Osaka, Japan
    • Saga
      • Saga-shi, Saga, Japan
    • Tokyo
      • Chuo-ku, Tokyo, Japan
      • Minato-ku, Tokyo, Japan
      • Musashino-shi, Tokyo, Japan
  • Korea, republiek van
    • Seoul
      • Gangnam-gu, Seoul, Korea, republiek van
      • Songpa-gu, Seoul, Korea, republiek van

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

20 jaar tot 80 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion criteria:

  1. Histologically or clinically confirmed diagnosis of advanced HCC.
  2. Eastern Cooperative Oncology Group-Performance Status (ECOG-PS): 0-1.
  3. Adequate laboratory values/organ function tests.

Exclusion criteria:

  1. Simultaneous or metachronous cancers.
  2. Pericardial, ascites, or pleural effusion requiring drainage.
  3. Brain metastasis/meningeal carcinomatosis presenting clinical symptoms or requiring treatment.
  4. Malabsorption syndrome.
  5. Artery-portal vein shunt or artery-vein shunt preventing proper diagnosis of tumor.
  6. Use of drugs known to inhibit cytochrome P3A4.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Lenvatinib
Geneesmiddel: Lenvatinib
In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
Andere namen:
  • E7080

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib
Tijdsspanne: Up to 28 days (Cycle1)
The MTD was defined as the highest dose level at which no more than 1 of 6 participants had a dose limiting toxicities (DLT). DLT was defined as any of the following events: grade 4 or higher hematologic toxicity or grade 3 thrombocytopenia that required blood transfusion, grade 3 or higher nonhematologic toxicity, grade 4 hypertension uncontrolled by antihypertensive drug(s), aspartate aminotransferase/alanine aminotransferase (AST/ALT) greater than (>) 10.0*upper limit of normal (ULN), proteinuria 4+ by urine dipstick, proteinuria 3+ by urine dipstick was to be monitored by 24-hour urine collection, proteinuria >3.5 gram (g) for 24 hours, diarrhea/vomiting/nausea of grade 3 or higher that was uncontrollable despite maximal supportive therapies and abnormal clinical laboratory values that required no treatment, grade 3 proteinuria by dipstick, diarrhea/vomiting/nausea that was managed with supportive therapies were not considered as DLT.
Up to 28 days (Cycle1)
Phase 2: Time to Progression (TTP) by Independent Review Assessment
Tijdsspanne: From day of registration to the day when PD was first confirmed (approximately up to 6.1 years)
TTP was defined as the time from the date of registration to the date when progressive disease (PD) was first confirmed. PD was evaluated according to modified response evaluation criteria in solid tumors (mRECIST) by an independent imaging review. PD was defined as at least a 20 percent (%) increase in the sum of long diameter (LD) of target lesions as compared with the smallest sum of LD and the increase of LD was at least 5 millimeter (mm) (including new lesions).
From day of registration to the day when PD was first confirmed (approximately up to 6.1 years)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Phase 1: Best Overall Response (BOR) of Lenvatinib by Investigator Assessment
Tijdsspanne: Every 8 weeks (approximately up to 18.4 months)
BOR was performed using RECIST1.1 and was measured as complete response (CR) defined as when an overall response of CR was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of CR was confirmed and the BOR established as CR was regarded as the "CR confirmed date), partial response (PR) defined as when the overall response of PR or better (CR or PR) was obtained 2 or more consecutive times at intervals of at least 28 days (the date when the second overall response of PR was confirmed and the BOR established as PR will be regarded as the "PR confirmed date), PD defined as when the BOR was neither CR, PR, or stable disease (SD), and the overall response was PD, SD defined as when the BOR obtained was neither CR nor PR, but no PD from the initial administration to the end of Cycle 2 and the overall response of SD or better occurred at least once and not evaluable (NE) was when the overall response was NE in all cases.
Every 8 weeks (approximately up to 18.4 months)
Phase 1: Objective Response Rate (ORR) by Investigator Assessment
Tijdsspanne: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
ORR was defined as the percentage of participants who achieved a tumor response measured by RECIST 1.1 of CR defined as disappearance of all target lesions (a short diameter is less than (<)10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Phase 1: Disease Control Rate (DCR) by Investigator Assessment
Tijdsspanne: Up to Week 16
DCR was measured by RECIST 1.1 and defined as CR which was defined as disappearance of all target lesions (a short diameter was <10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.
Up to Week 16
Phase 2: Progression-free Survival (PFS) by Independent Review Assessment
Tijdsspanne: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
PFS was defined as the time from the date of registration until the date when PD was first confirmed or death (whichever occurred first) as determined by mRECIST and PD was defined as at least a 20% increase in the sum of long diameters of target lesions, taking as reference the baseline sum of diameters of target lesions.
From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Phase 2: Objective Response Rate (ORR) by Independent Review Assessment
Tijdsspanne: From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
ORR was defined as the percentage of participants who achieved a tumor response measured by mRECIST of CR defined as disappearance of all target lesions (a short diameter is <10 mm if it exists in a lymph node) plus PR defined as at least 30% decrease in the sum of the long diameter LD (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.
From day of registration to the day when PD was first confirmed or death (approximately 6.1 years)
Phase 2: Disease Control Rate (DCR) by Independent Review Assessment
Tijdsspanne: Weeks 8 and 16
DCR was measured by mRECIST and defined as CR which was defined as disappearance of all target lesions (a short diameter is <10 mm if it exists in a lymph node) plus PR which was defined as at least 30% decrease in the sum of the long diameter (hereafter referred to as sum of LD) of all target lesions, as compared with baseline summed LD plus SD which was reduction in tumor volume of less than 50% or an increase in the volume of 1 or more measurable lesions of less than 25% without the appearance of any new lesions which was neither tumor shrinkage corresponding to PR nor tumor expansion corresponding to PD.
Weeks 8 and 16
Phase 2: Overall Survival (OS)
Tijdsspanne: From day of registration to the day of death (approximately 6.1 years)
OS was defined as the time from the date of registration until the date of death.
From day of registration to the day of death (approximately 6.1 years)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Eisai Co., Ltd.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 juli 2009

Primaire voltooiing (Werkelijk)

15 juni 2014

Studie voltooiing (Werkelijk)

13 augustus 2015

Studieregistratiedata

Eerst ingediend

23 juli 2009

Eerst ingediend dat voldeed aan de QC-criteria

23 juli 2009

Eerst geplaatst (Schatting)

24 juli 2009

Updates van studierecords

Laatste update geplaatst (Werkelijk)

1 februari 2019

Laatste update ingediend die voldeed aan QC-criteria

27 augustus 2018

Laatst geverifieerd

1 juli 2018

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • E7080-J081-202

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren